Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07157033 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
A Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma, sponsored by Xerient Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT07157033: Recruiting Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma, sponsored by Xerient Pharma.
NCT07157033 is a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Xerient Pharma. The registered enrollment target is 36 participants, below the 65-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07157033, a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Xerient Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
Primary Outcome
Incidence of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects
Conditions Studied
Interventions
- DRUG XER-001
Study Locations (2)
New Mexico
- Christus St. Vincent Regional Cancer Center - Santa Fe
Texas
- Oncology Consultants, P.A. - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2034-07-31 |
| Phase | Phase 1 |
What NCT07157033 shows while recruiting
NCT07157033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 65-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (45% lower).
The record links to 3 conditions, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which XER-001 is the first listed.
NCT07157033 reports a single indexed study location in New Mexico, Texas.
Frequently Asked Questions
What is clinical trial NCT07157033 about?
NCT07157033 is a clinical study titled "A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.". The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
What is the current status of trial NCT07157033?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-01-01. Estimated completion is 2034-07-31.
What conditions does trial NCT07157033 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreas Cancer.
What interventions are being tested in trial NCT07157033?
The interventions under investigation include: XER-001 (DRUG).
Who is sponsoring clinical trial NCT07157033?
This trial is sponsored by Xerient Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07157033 being conducted?
This trial has 2 study locations across New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07157033's enrollment target sits among peer trials
36 9th of 18 higher than 10 of 18 other Locally Advanced Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Locally Advanced Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RECRUITING · Phase 1
-
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 1
-
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
BATs Treatment for Pancreatic Cancer, Phase Ib/II
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI